Capricor's HOPE-3 Trial: Clear Path Ahead for DMD Treatment
Capricor's DMD drug (HOPE-3 trial) got key FDA alignment, speeding up the approval process using existing files. Data is expected mid-Q4, with potential approval by mid-2026. Shares jumped 9%.
Already have an account? Sign in.